The investigational cancer vaccine uses mRNA technology to help the immune system recognise and kill cancer cells containing human papillomavirus proteins.
More than 100 patients with advanced head and neck cancer in England will be matched to the trial, running at 15 NHS hospitals over the next year, supported by the NHS’ Cancer Vaccine Launch Pad (CVLP).
Read more – NHSE (8/8/25)